SCHEMBL2340955

SCHEMBL2340955

[c]1ncccc1-c1conn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4909130 0.72
SCHEMBL3759300 0.72 MDM2 (0.31)
SCHEMBL69569 0.72
SCHEMBL1925074 0.71 GOT1 (0.33)
SCHEMBL9199874 0.70 SCN9A (0.33)
SCHEMBL4843148 0.68
SCHEMBL6492459 0.68
SCHEMBL155358 0.67 KDM4E (0.52)
SCHEMBL7237023 0.64 CYP2A6 (0.52)
SCHEMBL291290 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113613655-A Compound and use thereof 诺维逊生物股份有限公司 2021-11-05 CN disclosed
EP-2194051-B1 Process for preparing compounds useful as intermediates for the preparation of modulators of chemokine receptor activity BRISTOL MYERS SQUIBB CO (US) 2011-08-31 EP disclosed
EP-1675838-A1 1-BENZOYL SUBSTITUTED DIAZEPINE DERIVATIVES AS SELECTIVE HISTAMINE H3 RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2006-07-05 EP disclosed
WO-2005040144-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2005-05-06 WO disclosed